Vertex Pharmaceuticals Inc (VRTX)

VRTX (NASDAQ:Drugs) EQUITY
$118.62
pos +0.82
+0.70%
Today's Range: 117.38 - 119.42 | VRTX Avg Daily Volume: 1,924,500
Last Update: 05/25/17 - 3:59 PM EDT
Volume: 1,194,567
YTD Performance: 59.90%
Open: $118.00
Previous Close: $117.80
52 Week Range: $75.90 - $143.45
Oustanding Shares: 249,068,782
Market Cap: 29,038,929,293
6-Month Chart
TheStreet Ratings Grade for VRTX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 8 7 6
Moderate Buy 1 1 2 2
Hold 8 8 9 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.03 1.97 2.08 2.19
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 166.56
Price Earnings Comparisons:
VRTX Sector Avg. S&P 500
166.56 0.00 29.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
36.87% 33.23% 65.82%
GROWTH 12 Mo 3 Yr CAGR
Revenue 64.90 0.40 0.12
Net Income 0.00 -0.90 0.00
EPS 0.00 -0.80 0.00
Earnings for VRTX:
EBITDA 0.07B
Revenue 1.70B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $0.05 $0.06 $0.42 $1.28
Number of Analysts 7 7 7 3
High Estimate $0.10 $0.15 $0.63 $1.82
Low Estimate $-0.05 $-0.05 $0.15 $0.90
Prior Year $-0.01 $-0.09 $-0.11 $0.42
Growth Rate (Year over Year) 642.86% 165.08% 479.22% 206.85%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
It's a wonder to me how split this market really is.
a mild winter goosed construction jobs service job data is so-so ISM services has just given back the entire post-election rise It might be time for a Ludacris forecast."   -- Kass Diary,
It's pretty normal to have profit-taking after such a strong first quarter.
Base building pays off.
Bullish
Mar 29, 2017 | 6:59 AM EDT
VRTX was upgraded from Market Perform to Outperform, BMO Capital said. $128 price target. Positive Phase III data suggests that triple ...
Bullish
Mar 17, 2017 | 7:02 AM EDT
VRTX was upgraded from Market Perform to Outperform, JMP Securities said. $115 price target. Expect positive data for cystic fibrosis p...
Even among the losers, buys are scarce.
Buy signals have not lasted more than two months, so far.
Bearish
Nov 29, 2016 | 7:50 AM EST
VRTX was downgraded from Overweight to Equal-weight, Barclays said. $90 price target. Company has an uncertain clinical profile.
What stocks have changed direction in the past week.

Columnist Conversations

View Chart »  View in New Window » View Chart » 

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.